| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON 19.11.2026 | 57 | Xetra Newsboard | The following instruments on XETRA do have their first trading 19.11.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 19.11.2026
Aktien
1 US03703U1079 Anthropic PBC
2 SG1BA1000003... ► Artikel lesen | |
| Di | IMPACT THERAP-B Senaparib Approved for Marketing in EU | 2 | AASTOCKS | ||
| IMPACT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | IMPACT THERAP-B (07630): INSIDE INFORMATION - APPROVAL BY THE EUROPEAN COMMISSION FOR MARKETING OF SENAPARIB | 1 | HKEx | ||
| 03.11. | IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | 1 | HKEx | ||
| 23.10. | IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - POSTER PRESENTATION OF LATEST CLINICAL DATA FOR SENAPARIB AND PARP1-SELECTIVE INHIBITORS IMP1734 AND ... | 1 | HKEx | ||
| 18.09. | IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - POSITIVE CHMP OPINION FOR SENAPARIB, AS POTENTIAL FIRST-LINE MAINTENANCE TREATMENT OF ADVANCED EPITHELIAL ... | - | HKEx | ||
| 18.09. | IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | 644 | Business Wire | For business and medical media onlyThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/Stephan Eder, CEO, Pharmanovia
IMPACT... ► Artikel lesen | |
| 14.09. | IMPACT THERAP-B (07630): 2026 INTERIM REPORT | 2 | HKEx | ||
| 07.09. | IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE STOCK LIST OF THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK ... | 1 | HKEx | ||
| 03.09. | IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER | 4 | HKEx | ||
| 31.08. | IMPACT THERAP-B (07630): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 24.08. | IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX | 1 | HKEx | ||
| 19.08. | IMPACT THERAP-B (07630): DATE OF BOARD MEETING | - | HKEx | ||
| 12.08. | IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - IMPACT THERAPEUTICS ANNOUNCES IMP2794 AS A PRECLINICAL CANDIDATE (PCC), A HIGHLY KAT6A-SPECIFIC PROTAC ... | 2 | HKEx | ||
| 11.08. | IMPACT THERAP-B (07630): PROFIT ALERT REDUCTION IN LOSS | 4 | HKEx | ||
| 03.08. | IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib | 1 | Pharmaceutical Technology | ||
| 31.07. | IMPACT THERAP-B (07630): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 31.07. | IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand | 506 | PR Newswire | SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with... ► Artikel lesen | |
| 31.07. | Impact Therapeutics licenses senaparib to Pharmanovia | 1 | Investing.com | ||
| 30.07. | IMPACT THERAP-B (07630): VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH PHARMANOVIA FOR SENAPARIB IN EUROPE, MIDDLE EAST AND NORTH AFRICA, ... | 1 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |